Inthera Bioscience
Stage
Series A | AliveTotal Raised
$14.8MLast Raised
$11.1M | 6 yrs agoAbout Inthera Bioscience
Inthera Bioscience, founded in 2013, employs a proprietary technology platform to rationally design protein-protein interaction inhibitors. The company has discovered disruptors of hypoxia-inducible signaling for the treatment of solid tumors and targeted agents against HPV- associated cancer, which are in pre-clinical development. Inthera Bioscience is a biopharmaceutical company focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform.
Missing: Inthera Bioscience's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Inthera Bioscience's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Inthera Bioscience
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Inthera Bioscience is included in 2 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Digital Health
13,119 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Inthera Bioscience Patents
Inthera Bioscience has filed 4 patents.
The 3 most popular patent topics include:
- Sedatives
- Small nuclear RNA
- Stereochemistry
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/3/2020 | 4/19/2022 | Small nuclear RNA, V8SuperTourer drivers, Stereochemistry, Trifluoromethyl compounds, Sedatives | Grant |
Application Date | 6/3/2020 |
|---|---|
Grant Date | 4/19/2022 |
Title | |
Related Topics | Small nuclear RNA, V8SuperTourer drivers, Stereochemistry, Trifluoromethyl compounds, Sedatives |
Status | Grant |
Latest Inthera Bioscience News
Jul 2, 2018
Inthera binds funding to series A round The cancer therapy developer has closed an $11.1m series A round featuring M Ventures and seed-stage backer Novo Seeds. Author: Callum Cyrus, Reporter Switzerland-based oncology therapy developer Inthera Bioscience has closed a series A round featuring subsidiaries of pharmaceutical firms Merck & Co and Novo at €9.6m ($11.1m). This rest of this content is only accessible to Global Corporate Venturing Subscribers This content is only accessible to subscribers. If you are a subscriber,please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Inthera Bioscience Frequently Asked Questions (FAQ)
Where is Inthera Bioscience's headquarters?
Inthera Bioscience's headquarters is located at Einsiedlerstrasse 34, Waedenswil.
What is Inthera Bioscience's latest funding round?
Inthera Bioscience's latest funding round is Series A.
How much did Inthera Bioscience raise?
Inthera Bioscience raised a total of $14.8M.
Who are the investors of Inthera Bioscience?
Investors of Inthera Bioscience include Novo Seeds, M Ventures, Aglaia Oncology Funds and Erfindungs Verwertung.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.